These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32383099)

  • 1. Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial.
    Cabarrou B; Gomez-Roca C; Viala M; Rabeau A; Paulon R; Loirat D; Munsch N; Delord JP; Filleron T
    Invest New Drugs; 2020 Dec; 38(6):1879-1887. PubMed ID: 32383099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy.
    Murakata Y; Tajiri K
    Intern Med; 2022 Jul; 61(14):2099-2100. PubMed ID: 35283387
    [No Abstract]   [Full Text] [Related]  

  • 3. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
    Majem M; García-Martínez E; Martinez M; Muñoz-Couselo E; Rodriguez-Abreu D; Alvarez R; Arance A; Berrocal A; de la Cruz-Merino L; Lopez-Martin JA
    Clin Transl Oncol; 2020 Feb; 22(2):213-222. PubMed ID: 31993963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why are immune adverse events so common with checkpoint inhibitor therapy?
    Lyubchenko T; Leung DYM; Goleva E
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):608-610. PubMed ID: 33774187
    [No Abstract]   [Full Text] [Related]  

  • 5. Endocrine adverse effects of immune checkpoint inhibitors.
    Walters AGB; Braatvedt G
    Intern Med J; 2021 Jul; 51(7):1016-1020. PubMed ID: 34278695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
    Fortes BH; Liou H; Dalvin LA
    Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
    Thanarajasingam G; Atherton PJ; Novotny PJ; Loprinzi CL; Sloan JA; Grothey A
    Lancet Oncol; 2016 May; 17(5):663-70. PubMed ID: 27083333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer.
    Chen C; Zhou Y; Zhang X; Wang Y; He LN; Lin Z; Chen T; Jiang Y; Hong S; Zhang L
    Front Immunol; 2021; 12():736943. PubMed ID: 34675926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management.
    Ruggiero R; Di Napoli R; Balzano N; Ruggiero D; Riccardi C; Anatriello A; Cantone A; Sportiello L; Rossi F; Capuano A
    Expert Rev Clin Pharmacol; 2023 May; 16(5):423-434. PubMed ID: 37144360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
    Khan OF; Monzon J
    Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine toxicities of immune checkpoint inhibitors.
    Wright JJ; Powers AC; Johnson DB
    Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies.
    Voon PJ; Cella D; Hansen AR
    Cancer; 2021 May; 127(9):1360-1368. PubMed ID: 33662145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy-related adverse events: causes and challenges.
    Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
    Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.
    Makunts T; Saunders IM; Cohen IV; Li M; Moumedjian T; Issa MA; Burkhart K; Lee P; Patel SP; Abagyan R
    Sci Rep; 2021 Aug; 11(1):17324. PubMed ID: 34462476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
    BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist.
    Furtado VF; Melamud K; Hassan K; Rohatgi S; Buch K
    Clin Imaging; 2020 Jul; 63():35-49. PubMed ID: 32120311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.